• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心房颤动诱发的心动过速性心肌病与心力衰竭:一种未得到充分认识且难以捉摸的病症。

Atrial fibrillation-induced tachycardiomyopathy and heart failure: an underappreciated and elusive condition.

作者信息

Manolis Antonis S, Manolis Theodora A, Manolis Antonis A, Melita Helen

机构信息

First Department of Cardiology, Athens University School of Medicine, Athens, Greece.

Aghia Sofia University Hospital, Athens, Greece.

出版信息

Heart Fail Rev. 2022 Nov;27(6):2119-2135. doi: 10.1007/s10741-022-10221-1. Epub 2022 Mar 23.

DOI:10.1007/s10741-022-10221-1
PMID:35318562
Abstract

Many patients with persistent, chronic, or frequently recurring paroxysmal atrial fibrillation (AF) may develop a tachycardiomyopathy (TCM) with left ventricular (LV) dysfunction and heart failure (HF), which is reversible upon restoration and maintenance of sinus rhythm, when feasible, or via better and tighter ventricular rate (VR) control. Mechanisms involved in producing this leading cause of TCM (AF-TCM) include loss of atrial contraction, irregular heart rate, fast VR, neurohumoral activation, and structural myocardial changes. The most important of all mechanisms relates to optimal VR control, which seems to be an elusive target. Uncontrolled AF may also worsen preexisting LV dysfunction and exacerbate HF symptoms. Data, albeit less robust, also point to deleterious effects of slow VRs on LV function. Thus, a J-shaped relationship between VR and clinical outcome has been suggested, with the optimal VR control hovering at ~ 65 bpm, ranging between 60 and 80 bpm; VRs above and below this range may confer higher morbidity and mortality rates. A convergence of recent guidelines is noted towards a stricter rather than a more lenient VR control with target heart rate < 80 bpm at rest and < 110 bpm during moderate exercise which seems to prevent TCM or improve LV function and exercise capacity and relieve TCM-related symptoms and signs. Of course, restoring and maintaining sinus rhythm is always a most desirable target, when feasible, either with drugs or more likely with ablation. All these issues are herein reviewed, current guidelines are discussed and relevant data are tabulated and pictorially illustrated.

摘要

许多持续性、慢性或频繁复发的阵发性心房颤动(AF)患者可能会发展为心动过速性心肌病(TCM),伴有左心室(LV)功能障碍和心力衰竭(HF),在可行的情况下,通过恢复和维持窦性心律,或通过更好、更严格的心室率(VR)控制,这种情况是可逆的。导致这种TCM主要病因(AF-TCM)的机制包括心房收缩丧失、心率不规则、快速VR、神经体液激活和心肌结构改变。所有机制中最重要的与最佳VR控制有关,而这似乎是一个难以实现的目标。未控制的AF也可能使已有的LV功能障碍恶化,并加重HF症状。尽管数据不太充分,但也表明缓慢的VR对LV功能有有害影响。因此,有人提出VR与临床结局之间呈J形关系,最佳VR控制徘徊在约65次/分,范围在60至80次/分之间;高于和低于此范围的VR可能导致更高的发病率和死亡率。最近的指南趋于一致,倾向于更严格而非更宽松的VR控制,目标心率为静息时<80次/分,中度运动时<110次/分,这似乎可以预防TCM或改善LV功能和运动能力,并缓解与TCM相关的症状和体征。当然,在可行的情况下,无论是使用药物还是更可能通过消融来恢复和维持窦性心律始终是最理想的目标。本文对所有这些问题进行了综述,讨论了当前指南,并将相关数据制成表格并以图表形式说明。

相似文献

1
Atrial fibrillation-induced tachycardiomyopathy and heart failure: an underappreciated and elusive condition.心房颤动诱发的心动过速性心肌病与心力衰竭:一种未得到充分认识且难以捉摸的病症。
Heart Fail Rev. 2022 Nov;27(6):2119-2135. doi: 10.1007/s10741-022-10221-1. Epub 2022 Mar 23.
2
Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation.心房颤动和典型心房扑动的根治性导管消融术:系统评价与经济评估
Health Technol Assess. 2008 Nov;12(34):iii-iv, xi-xiii, 1-198. doi: 10.3310/hta12340.
3
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
4
Atrial Fibrillation: A Review.心房颤动:综述
JAMA. 2025 Jan 28;333(4):329-342. doi: 10.1001/jama.2024.22451.
5
Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.“口袋里的药丸”策略与偶发性院内治疗或持续性抗心律失常药物治疗相比,用于阵发性心房颤动的系统评价和成本效益评估。
Health Technol Assess. 2010 Jun;14(31):iii-iv, 1-75. doi: 10.3310/hta14310.
6
External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis.体外电复律和药物复律治疗心房颤动、心房扑动或房性心动过速的网状 Meta 分析。
Cochrane Database Syst Rev. 2024 Jun 3;6(6):CD013255. doi: 10.1002/14651858.CD013255.pub2.
7
Systematic review of the management of atrial fibrillation in patients with heart failure.心力衰竭患者心房颤动管理的系统评价
Eur Heart J. 2000 Apr;21(8):614-32. doi: 10.1053/euhj.1999.1767.
8
Catheter ablation for atrial fibrillation in patients with left ventricular systolic dysfunction. A systematic review and meta-analysis.导管消融治疗左心室收缩功能障碍患者的心房颤动:系统评价和荟萃分析。
J Card Fail. 2011 Nov;17(11):964-70. doi: 10.1016/j.cardfail.2011.07.009. Epub 2011 Sep 9.
9
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.静脉注射硫酸镁和索他洛尔预防冠状动脉搭桥术后房颤:系统评价与经济学评估
Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. doi: 10.3310/hta12280.
10
Early Left Ventricular Reverse Remodeling After Catheter Ablation of Atrial Fibrillation is Associated With Lower Recurrence Rates and Improved Prognosis in Patients With Left Ventricular Systolic Dysfunction.房颤导管消融术后早期左心室逆向重构与左心室收缩功能障碍患者较低的复发率及改善的预后相关。
J Cardiovasc Electrophysiol. 2025 Jul;36(7):1548-1558. doi: 10.1111/jce.16706. Epub 2025 May 5.

引用本文的文献

1
Exercise and Atrial Fibrillation: Current Evidence, Knowledge Gaps, and Future Directions.运动与心房颤动:当前证据、知识空白及未来方向
Rev Cardiovasc Med. 2025 Jul 28;26(7):39200. doi: 10.31083/RCM39200. eCollection 2025 Jul.
2
Factors influencing the development of heart failure after PCI in patients with acute coronary syndrome: a meta-analysis.急性冠状动脉综合征患者经皮冠状动脉介入治疗后心力衰竭发生的影响因素:一项荟萃分析
Am J Transl Res. 2025 Apr 15;17(4):2352-2375. doi: 10.62347/FPXH3010. eCollection 2025.
3
Global trends and regional disparities in atrial fibrillation and flutter burden attributable to high alcohol consumption: findings from the global burden of disease study 2021.

本文引用的文献

1
Successful Reversal of Severe Tachycardia-Induced Cardiomyopathy with Cardiogenic Shock by Urgent Rhythm or Rate Control: Only Rhythm and Rate Matter.通过紧急节律或心率控制成功逆转伴有心源性休克的严重心动过速性心肌病:唯有节律和心率起作用。
J Clin Med. 2021 Sep 29;10(19):4504. doi: 10.3390/jcm10194504.
2
Pace and ablate better than drugs in patients with heart failure and atrial fibrillation: lessons from the APAF-CRT mortality trial.
Eur Heart J. 2021 Dec 7;42(46):4740-4742. doi: 10.1093/eurheartj/ehab695.
3
AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial.房室结消融联合心脏再同步治疗永久性心房颤动伴窄 QRS 波患者:APAF-CRT 死亡率试验。
高酒精摄入量所致心房颤动和心房扑动负担的全球趋势与地区差异:2021年全球疾病负担研究的结果
BMC Cardiovasc Disord. 2025 Apr 7;25(1):266. doi: 10.1186/s12872-025-04699-4.
4
Up-titration of medication in patients with new-onset heart failure with and without atrial fibrillation.新发心力衰竭伴或不伴心房颤动患者的药物剂量递增
ESC Heart Fail. 2025 Jun;12(3):1703-1713. doi: 10.1002/ehf2.15188. Epub 2025 Feb 19.
5
Current Strategies for Atrial Fibrillation Prevention and Management: Taming the Commonest Cardiac Arrhythmia.心房颤动预防与管理的当前策略:驯服最常见的心律失常
Curr Vasc Pharmacol. 2025;23(1):31-44. doi: 10.2174/0115701611317504240910113003.
6
Soluble ST2 for predicting heart failure, atrial fibrillation and death in patients with coronary heart disease with or without renal insufficiency.可溶性ST2用于预测伴或不伴肾功能不全的冠心病患者发生心力衰竭、心房颤动及死亡的情况。
Heliyon. 2024 Apr 20;10(9):e29804. doi: 10.1016/j.heliyon.2024.e29804. eCollection 2024 May 15.
7
The risk of stroke recurrence in patients with atrial fibrillation and reduced ejection fraction.心房颤动伴射血分数降低患者的卒中复发风险。
Eur Stroke J. 2023 Sep;8(3):731-737. doi: 10.1177/23969873231177625. Epub 2023 May 30.
8
Intestinal Barrier Dysfunction and Microbial Translocation in Patients with First-Diagnosed Atrial Fibrillation.初诊房颤患者的肠道屏障功能障碍与微生物易位
Biomedicines. 2023 Jan 10;11(1):176. doi: 10.3390/biomedicines11010176.
9
Prevalence and prognostic role of L wave and selected clinical and echocardiographic variables in dogs with atrial fibrillation.心房颤动犬中 L 波的发生率和预后作用及部分临床和超声心动图变量。
J Vet Intern Med. 2023 Jan;37(1):47-57. doi: 10.1111/jvim.16584. Epub 2022 Dec 8.
Eur Heart J. 2021 Dec 7;42(46):4731-4739. doi: 10.1093/eurheartj/ehab569.
4
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南。
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
5
The effect of controlling the heart rate on the heart failure index and on heart function in heart failure patients with atrial fibrillation.控制心率对伴有心房颤动的心力衰竭患者心力衰竭指数及心脏功能的影响。
Am J Transl Res. 2021 Apr 15;13(4):3487-3493. eCollection 2021.
6
Predictors of myocardial recovery in arrhythmia-induced cardiomyopathy: A multicenter study.心律失常性心肌病心肌恢复的预测因素:一项多中心研究。
J Cardiovasc Electrophysiol. 2021 Apr;32(4):1085-1092. doi: 10.1111/jce.14963. Epub 2021 Mar 4.
7
Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial.心房颤动心力衰竭中消融与药物治疗的比较:CABANA 试验结果。
Circulation. 2021 Apr 6;143(14):1377-1390. doi: 10.1161/CIRCULATIONAHA.120.050991. Epub 2021 Feb 8.
8
Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.心脏病与中风统计-2021 更新:美国心脏协会报告。
Circulation. 2021 Feb 23;143(8):e254-e743. doi: 10.1161/CIR.0000000000000950. Epub 2021 Jan 27.
9
Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.心房颤动患者的早期节律控制治疗。
N Engl J Med. 2020 Oct 1;383(14):1305-1316. doi: 10.1056/NEJMoa2019422. Epub 2020 Aug 29.
10
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.2020年欧洲心脏病学会(ESC)与欧洲心胸外科学会(EACTS)合作制定的心房颤动诊断和管理指南:欧洲心脏病学会(ESC)心房颤动诊断和管理特别工作组,由ESC欧洲心律协会(EHRA)特别贡献制定。
Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.